Patent details

LUC00272 Product Name: Rimégépant ou un de ses sels pharmaceutiquement acceptables

Basic Information

Publication number:
LUC00272
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP107683476
Legal Status:
Inactive
Application number:
LUC00272
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/22/1645
Marketing Authorization Type:
Marketing Authorization Date:
26/04/2022
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
19/07/2022
First Marketing Authorization date:
26/04/2022
Grant date:
12/05/2025
Activation date:
Publication date:
21/07/2022
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
13/10/2035
SPC Extension Expiration:
13/10/2035
Rejection date:
Withdrawal date:

Owner

From:
19/07/2022
 
 

Name:
Bristol-Myers Squibb Company
Address:
Route 206 & Province Line Road, Princeton, NJ 08543-4000, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
19/07/2022
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2022/09
Publication date:
01/08/2022
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2025/07
Publication date:
04/06/2025
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
31/10/2030
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
19/07/2022 Application Form 3
19/07/2022 Marketing authorization 3
19/07/2022 Summary of the product caracteristics 32
19/07/2022 MA publication 11
21/07/2022 Outgoing Correspondence 1
21/07/2022 Publication 1
12/05/2025 Publication 1
12/05/2025 Certificate 1
12/05/2025 Outgoing Correspondence 1